beclabuvir

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
024620152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Daclatasvir (DCV; non-structural [NS]5A inhibitor) plus asunaprevir (ASV; NS3 inhibitor) plus beclabuvir (BCV; non… (More)
Is this relevant?
2017
2017
BACKGROUND & AIMS The phase 2, FOURward study (NCT02175966) investigated short-duration therapy (4/6 weeks) with four direct… (More)
  • table 1
  • table 2
Is this relevant?
2017
2017
The oral absolute bioavailability of beclabuvir in healthy subjects was determined using a microdose (100μg) of the stable… (More)
Is this relevant?
2016
2016
DCV-TRIO, a fixed-dose combination of daclatasvir (pangenotypic NS5A inhibitor), asunaprevir (NS3/4A protease inhibitor), and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
Asunaprevir (ASV), daclatasvir (DCV), and beclabuvir (BCV) are three drugs developed for the treatment of chronic hepatitis C… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2015
2015
IMPORTANCE Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2015
2015
LB-7. Tarek Hassanein1,⇑ Karen D. Sims Michael Bennett Norman Gitlin Eric Lawitz Tuan Nguyen Lynn Webster Zobair Younossi Howard… (More)
  • table 1
Is this relevant?
2015
2015
Dual or triple combination regimens of novel hepatitis C direct-acting antivirals (DAA, daclatasvir, asunaprevir, or beclabuvir… (More)
  • figure 2
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2015
Review
2015
INTRODUCTION About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most… (More)
Is this relevant?
2015
2015
Beclabuvir is a potent, non-nucleoside inhibitor of the HCV NS5B RNA polymerase, with nanomolar activity against HCV genotypes 1… (More)
Is this relevant?